July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Clinical Characteristics of Eyes with Steroid Use in a Japanese Glaucoma Clinic
Author Affiliations & Notes
  • Kenji Suda
    Ophthalmology, Kyoto University, Kyoto, Japan
  • Tadamichi Akagi
    Ophthalmology, Kyoto University, Kyoto, Japan
  • Ikeda Ohashi Hanako
    Ophthalmology, Kyoto University, Kyoto, Japan
  • Takanori Kameda
    Ophthalmology, Kyoto University, Kyoto, Japan
  • tomoko hasegawa
    Ophthalmology, Kyoto University, Kyoto, Japan
  • Hideo Nakanishi
    Ophthalmology, Kyoto University, Kyoto, Japan
  • Satoshi Morooka
    Ophthalmology, Kyoto University, Kyoto, Japan
  • Akitaka Tsujikawa
    Ophthalmology, Kyoto University, Kyoto, Japan
  • Footnotes
    Commercial Relationships   Kenji Suda, Alcon Japan (F), Otsuka Pharmaceutical (R); Tadamichi Akagi, None; Ikeda Hanako, None; Takanori Kameda, None; tomoko hasegawa, None; Hideo Nakanishi, None; Satoshi Morooka, None; Akitaka Tsujikawa, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1961. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kenji Suda, Tadamichi Akagi, Ikeda Ohashi Hanako, Takanori Kameda, tomoko hasegawa, Hideo Nakanishi, Satoshi Morooka, Akitaka Tsujikawa; Clinical Characteristics of Eyes with Steroid Use in a Japanese Glaucoma Clinic. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1961.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Steroid-induced glaucoma is famous for side effect of steroid use, but epidemiology of steroid-induced glaucoma in Japan has not been illustrated well. Our aim in this study is to reveal the clinical characteristics of eyes with steroid use in Japanese glaucoma clinics.

Methods : Patients with steroid use who had visited the glaucoma clinic in Kyoto University Hospital between August 2011 and October 2017 were included. We investigated their age at first visit and mean deviation (MD) of visual field tests (Humphrey field analyzer (HFA) SITA Standard 24-2) at first and final visits, and highest intraocular pressure (IOP) in the clinical record and compared their average between the reasons for steroid use. The correlation between two parameters among age, MD and highest IOP was evaluated by Pearson’s correlation coefficient.

Results : A total of 382 eyes of 196 patients (mean age, 52.4 ± 18.3 years) were included. The average of MD was -6.6 ± 7.1 dB at first visit and -7.6 ± 8.0 dB at final visit (mean observation duration, 82.3 ± 48.0 months). The average of highest IOP was 26.9 ± 10.9 mmHg. The most frequent disease as the reason of steroid use was atopic dermatitis (58 eyes), followed by autoimmune diseases (systemic lupus erythematosus 44 eyes; interstitial pneumonia 26 eyes; rheumatoid arthritis 26 eyes). The patients with atopic dermatitis was significantly younger (38.0 ± 11.2 years old, p < 0.001) and had lower MD (-9.3 ± 9.1 dB at first visit, p = 0.01; -10.6 ± 9.2 dB at final visit, p = 0.004) than those with other diseases. Highest IOP in the clinical course was correlated significantly with MD at final visit (r = -0.41, p < 0.001).

Conclusions : Patients with atopic dermatitis have high risk of visual field loss at an early age. Regular measurement of intraocular pressure is essential for preventing glaucoma progression.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

The correlation between two parameters among age, MD and highest IOP. The red dots in the scatter plots represent eyes with atopic dermatitis.

The correlation between two parameters among age, MD and highest IOP. The red dots in the scatter plots represent eyes with atopic dermatitis.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×